Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA-2808
- Development stage
- Phase 2
- Lead developer
- Moderna
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
mRNA-2808 is an investigational, **multispecific mRNA-encoded T-cell engager therapy** developed for oncology indications, specifically multiple myeloma. It encodes several T-cell engagers in a single product, potentially targeting BCMA, Fc receptor homolog 5 (FcRH5), and G-protein coupled receptor family C group 5 member D (GPRC5D). The mechanism involves instructing cells to produce multispecific T-cell engagers that redirect T cells to kill malignant plasma cells expressing these antigens. Developed by Moderna, mRNA-2808 is currently in Phase 1/2 clinical trials for relapsed or refractory multiple myeloma. This candidate represents a novel application of mRNA technology for immuno-oncology, aiming to enhance the specificity and potency of T-cell redirection against cancer cells[1][3][5][7][8][9].
- Brand names
- mRNA-2808mRNA2808mRNA 2808
- Other names
- mRNA-2808mRNA2808mRNA 2808
02
Targets
FCRL5 (Fc receptor-like protein 5)GPRC5DBCMA (B-cell maturation antigen)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on mRNA-2808.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA-2808.